• FDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer

    Source: NASDAQ Stocks / 02 Jun 2023 13:10:44   America/Chicago

    AstraZeneca AZN and Merck MRK announced that the FDA approved the expansion of their PARP inhibitor Lynparza (olaparib) in prostate cancer indication https://www.nasdaq.com/articles/fda-expands-astrazeneca-azn-lynparza-label-in-prostate-cancer
Share on,